Výsledky vyhledávání

Efficacy of ertugliflozin on hospitalisation for heart failure across the distribution of pre-trial ejection fraction: post hoc analyses of the VERTIS CV trial

Autor: A Pandey, A A Kolkailah, F Cosentino, C P Cannon, R Frederich, D Z I Cherney, S Dagogo-Jack, R E Pratley, N B Cater, I Gantz, J P Mancuso, D K McGuire

Publikováno v: European Heart Journal. 43

Introduction There is controversy over whether SGLT2 inhibitors have efficacy in high-risk patients with heart failure (HF) and ejection fraction (EF) >60% with or without type 2 diabetes (T2D). The VERTIS CV trial studied a population of patients wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bf7752a457084631c712696b851cf994
https://doi.org/10.1093/eurheartj/ehac544.962

Zobrazit plný text záznamu

Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial

Autor: F Cosentino, C P Cannon, D Z I Cherney, S Dagogo-Jack, R E Pratley, B Charbonnel, W J Shih, J P Mancuso, M Maldonado, R Frederich, N B Cater, S Wang, D K McGuire

Publikováno v: European Heart Journal. 42

Introduction We analysed data from the VERTIS CV trial that investigated the CV and kidney safety and efficacy of the sodium-glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin (ERTU) vs placebo (PBO) to assess the impact of metformin (MET) use a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::40546bdf2d98a520b0d92f68efc6f34b
https://doi.org/10.1093/eurheartj/ehab724.2650

Zobrazit plný text záznamu

Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial

Autor: M W Segar, A Pandey, D Z I Cherney, C P Cannon, F Cosentino, S Dagogo-Jack, R E Pratley, W J Shih, R Frederich, N B Cater, M Maldonado, J Liu, C Liu, A Pong, D K McGuire

Publikováno v: European Heart Journal. 42

Introduction Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce risk of hospitalisation for heart failure (HHF) in outcome trials, but the biological mediators underlying the therapeutic benefit are not well established. Purpose To identify pot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::238e0337f093b1e9c38f0d650c770887
https://doi.org/10.1093/eurheartj/ehab724.2649

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání